1. Home
  2. RVPH vs HOWL Comparison

RVPH vs HOWL Comparison

Compare RVPH & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • HOWL
  • Stock Information
  • Founded
  • RVPH 2006
  • HOWL 2017
  • Country
  • RVPH United States
  • HOWL United States
  • Employees
  • RVPH N/A
  • HOWL N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • HOWL Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVPH Health Care
  • HOWL Health Care
  • Exchange
  • RVPH Nasdaq
  • HOWL Nasdaq
  • Market Cap
  • RVPH 88.0M
  • HOWL 87.4M
  • IPO Year
  • RVPH N/A
  • HOWL 2021
  • Fundamental
  • Price
  • RVPH $2.09
  • HOWL $1.36
  • Analyst Decision
  • RVPH Strong Buy
  • HOWL Strong Buy
  • Analyst Count
  • RVPH 5
  • HOWL 2
  • Target Price
  • RVPH $11.40
  • HOWL $9.50
  • AVG Volume (30 Days)
  • RVPH 1.8M
  • HOWL 269.3K
  • Earning Date
  • RVPH 11-14-2024
  • HOWL 03-06-2025
  • Dividend Yield
  • RVPH N/A
  • HOWL N/A
  • EPS Growth
  • RVPH N/A
  • HOWL N/A
  • EPS
  • RVPH N/A
  • HOWL N/A
  • Revenue
  • RVPH N/A
  • HOWL $3,386,000.00
  • Revenue This Year
  • RVPH N/A
  • HOWL N/A
  • Revenue Next Year
  • RVPH N/A
  • HOWL $34.17
  • P/E Ratio
  • RVPH N/A
  • HOWL N/A
  • Revenue Growth
  • RVPH N/A
  • HOWL N/A
  • 52 Week Low
  • RVPH $0.60
  • HOWL $1.26
  • 52 Week High
  • RVPH $4.83
  • HOWL $8.19
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 60.41
  • HOWL 41.40
  • Support Level
  • RVPH $1.78
  • HOWL $1.26
  • Resistance Level
  • RVPH $2.15
  • HOWL $1.45
  • Average True Range (ATR)
  • RVPH 0.15
  • HOWL 0.09
  • MACD
  • RVPH 0.02
  • HOWL 0.02
  • Stochastic Oscillator
  • RVPH 88.30
  • HOWL 45.45

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Share on Social Networks: